Unapproved peptide product promoters and suppliers are put on notice
Published
Related content
-
TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response
We have expanded our priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety. -
TGA releases updated social media advertising guidance to support improved compliance
The TGA has updated its Advertising therapeutic goods on social media guidance to help advertisers to understand their responsibilities when promoting therapeutic goods via these platforms. -
Concerns regarding the public health risks associated with unapproved peptide products
Australia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.